Latest Period
Q2 2026
Security Snapshot
ANI PHARMACEUTICALS INC - Common Stock (ANIP) Institutional Ownership
CUSIP: 00182C103
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
304
Shares (Excl. Options)
22,909,772
Price
$82.78
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ANIP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 22,909,772
- Total 13F value
- $1,896,950,386
- Portfolio coverage rank
- 0%
- Share change
- -430,447
- Value change
- -$27,262,315
- Number of holders
- 304
- Shares outstanding
- 22,655,023
- SEC-reported price per share
- $77.61
- Insider filing price
- $77.61
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ANIP - ANI PHARMACEUTICALS INC - Common Stock is tracked under CUSIP 00182C103.
- 304 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 278 to 304 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,797,082,051 to $1,896,950,386.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 304 institutions filings for Q2 2026.
Security key
00182C103
Latest holder period
Q2 2026
13F holders
304
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
ANIP full holder history
ANI PHARMACEUTICALS INC SEC filings
ANI PHARMACEUTICALS INC company facts
ANI PHARMACEUTICALS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00182C103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
ANIP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13% | +14% | $240,049,004 | +$31,656,645 | 2,899,843 | +15% | BlackRock, Inc. | 30 Jun 2026 |
| Meridian Venture Partners II GP, L.P. | 4.8% | -12% | $66,419,394 | -$9,630,000 | 1,034,570 | -13% | Robert E. Brown, Jr. | 21 Aug 2025 |
| MILLENNIUM MANAGEMENT LLC | 3.8% | -28% | $57,136,569 | -$19,037,261 | 818,341 | -25% | Millennium Management LLC | 31 Mar 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC | 0.3% | -98% | $5,976,442 | -$96,309,614 | 65,245 | -94% | Millennium Management LLC | 30 Sep 2025 |
As of 30 Jun 2026, 304 institutional investors reported holding 22,909,772 shares of ANI PHARMACEUTICALS INC - Common Stock (ANIP). This represents 101% of the company’s total 22,655,023 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
61%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13% | 2,958,646 | +7.7% | 0% | $244,916,714 |
| Soleus Capital Management, L.P. | 3.8% | 867,760 | +5.8% | 2.5% | $71,833,173 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 838,224 | +1.8% | 0% | $69,388,183 |
| STATE STREET CORP | 3.7% | 831,647 | +7.8% | 0% | $68,855,281 |
| TANG CAPITAL MANAGEMENT LLC | 3.1% | 707,500 | 0% | 2.7% | $58,566,850 |
| DIMENSIONAL FUND ADVISORS LP | 2.8% | 623,463 | +17% | 0.01% | $51,613,558 |
| AMERICAN CENTURY COMPANIES INC | 2.5% | 574,474 | +200% | 0.02% | $47,554,958 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.5% | 562,016 | -0.42% | 0.02% | $46,523,684 |
| Global Alpha Capital Management Ltd. | 2.5% | 558,003 | +54% | 2.8% | $46,191,488 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 536,407 | +9.6% | 0% | $44,411,791 |
| MILLENNIUM MANAGEMENT LLC | 2.2% | 507,207 | -14% | 0.03% | $41,986,595 |
| Nuveen, LLC | 1.8% | 415,024 | +3.1% | 0.01% | $34,355,687 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.8% | 407,281 | +8.3% | 0% | $33,714,721 |
| Ranger Investment Management, L.P. | 1.5% | 343,150 | -4.7% | 1.8% | $28,405,957 |
| DEUTSCHE BANK AG\ | 1.4% | 323,443 | +1.2% | 0.01% | $26,774,611 |
| Invesco Ltd. | 1.4% | 309,233 | -4.7% | 0% | $25,598,308 |
| UBS Group AG | 1.3% | 297,539 | -40% | 0% | $24,630,278 |
| KENNEDY CAPITAL MANAGEMENT LLC | 1.3% | 295,938 | +0.66% | 0.43% | $24,497,748 |
| AMERIPRISE FINANCIAL INC | 1.3% | 287,382 | +6.3% | 0% | $23,789,485 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.3% | 287,206 | -0.12% | 0.04% | $23,775,000 |
| Ikarian Capital, LLC | 1.2% | 272,085 | +85% | 3.7% | $22,523,196 |
| Aberdeen Group plc | 1.2% | 271,760 | +32% | 0.03% | $22,496,293 |
| OBERWEIS ASSET MANAGEMENT INC/ | 1.2% | 265,306 | +20% | 0.45% | $21,962,031 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.1% | 258,173 | -21% | 0.06% | $21,371,561 |
| Rubric Capital Management LP | 1.1% | 258,131 | 0.2% | $21,368,084 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 22,909,772 | $1,896,950,386 | -$27,262,315 | $82.78 | 304 |
| 2026 Q1 | 23,377,686 | $1,797,082,051 | +$144,062,868 | $76.90 | 278 |
| 2025 Q4 | 21,151,784 | $1,669,959,225 | +$30,069,338 | $78.94 | 284 |
| 2025 Q3 | 20,389,328 | $1,867,651,983 | +$52,854,102 | $91.60 | 266 |
| 2025 Q2 | 19,725,780 | $1,287,090,849 | -$20,870,018 | $65.25 | 229 |
| 2025 Q1 | 19,963,692 | $1,336,584,283 | +$48,405,121 | $66.95 | 226 |
| 2024 Q4 | 19,278,460 | $1,065,666,126 | +$20,364,527 | $55.28 | 204 |
| 2024 Q3 | 18,878,833 | $1,126,182,384 | +$220,571,922 | $59.66 | 207 |
| 2024 Q2 | 15,122,528 | $963,007,127 | +$64,529,569 | $63.68 | 200 |
| 2024 Q1 | 14,090,492 | $974,037,268 | +$37,316,448 | $69.13 | 195 |
| 2023 Q4 | 13,616,342 | $750,788,600 | +$15,033,397 | $55.14 | 180 |
| 2023 Q3 | 13,199,659 | $766,379,240 | +$52,240,515 | $58.06 | 184 |
| 2023 Q2 | 12,299,725 | $662,081,429 | +$105,431,062 | $53.83 | 169 |
| 2023 Q1 | 10,365,411 | $411,702,884 | +$7,764,406 | $39.72 | 137 |
| 2022 Q4 | 10,254,354 | $412,610,775 | +$2,387,720 | $40.23 | 125 |
| 2022 Q3 | 10,269,268 | $330,253,290 | +$12,871,843 | $32.14 | 115 |
| 2022 Q2 | 9,879,095 | $293,397,646 | +$29,894,218 | $29.67 | 109 |
| 2022 Q1 | 9,205,000 | $258,822,043 | -$5,750,270 | $28.11 | 115 |
| 2021 Q4 | 8,972,675 | $413,375,358 | +$78,226,286 | $46.08 | 126 |
| 2021 Q3 | 7,280,546 | $238,830,760 | +$14,353,157 | $32.82 | 105 |
| 2021 Q2 | 7,204,407 | $252,488,638 | -$2,871,513 | $35.05 | 104 |
| 2021 Q1 | 7,293,016 | $263,483,493 | +$391,549 | $36.14 | 100 |
| 2020 Q4 | 7,361,043 | $213,798,867 | +$1,986,104 | $29.04 | 109 |
| 2020 Q3 | 7,312,777 | $206,302,713 | -$6,295,496 | $28.21 | 105 |
| 2020 Q2 | 7,466,801 | $241,329,748 | -$25,517,337 | $32.34 | 124 |